Artiva Biotherapeutics vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Artiva Biotherapeutics develops off-the-shelf allogeneic natural killer (NK) cell therapies for cancer; lead program AB-101 targets B-cell malignancies and autoimmune disease; raised over $230M including a $150M Series C;
About
Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company founded in 2019 with a mission to develop off-the-shelf, allogeneic natural killer (NK) cell therapies that can transform cancer treatment. NK cells are innate immune cells that can identify and kill cancer cells without requiring the patient-specific manufacturing that makes autologous CAR-T therapies so expensive and logistically complex. Artiva's allogeneic (donor-derived) approach enables manufacturing at scale from healthy donors, producing standardized cell therapy products that can be stored and shipped like conventional drugs.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Artiva Biotherapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.